Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Ezetimibe · 2 trials · 3 indications
Percent change in LDL-C = (Combination treatment value - Baseline value)/Baseline value\*100
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Rosuvastatin 40mg/Ezetimibe 10mg combination therapy |
| 2 | EXPERIMENTAL | Rosuvastatin 40 mg |
| Name | Type | Description |
|---|---|---|
| Rosuvastatin (Crestor) | DRUG | 10mg and 20 mg |
| Ezetimibe | DRUG | 10 mg |
| Simvastatin | DRUG | 40mg and 80 mg |
| Rosuvastatin | DRUG | 40mg |
Inclusion Criteria: * Patients with with hypercholesterolaemia and CHD or a CHD risk equivalent, clinical evidence of atherosclerosis or a Framingham 10-year CHD risk score of \>20 * Patients will need to sign an informed consent before any visit procedures can be performed, including procedures fo...
Ezetimibe is used for hypercholesterolemia, a condition of high cholesterol. It is being studied in combination with rosuvastatin for patients with hypercholesterolemia, coronary heart disease, and atherosclerosis. The drug is in Phase 3 clinical development and is not yet approved.
Ezetimibe is being developed by AstraZeneca PLC, which trades under the ticker AZN. The company is conducting Phase 3 clinical trials for the drug in hypercholesterolemia.
Ezetimibe is in Phase 3 clinical development. It is an investigational drug and has not been approved. Two Phase 3 trials have been completed, with a total enrollment of 1,743 participants.
Ezetimibe has two completed Phase 3 trials: NCT00525824, a 12-week open-label study comparing rosuvastatin in combination with ezetimibe, enrolling 1,743 patients; and NCT00653445, comparing rosuvastatin 40mg with ezetimibe 10mg. Both studied hypercholesterolemia, coronary heart disease, and atherosclerosis.
Ezetimibe is a small molecule that works by targeting cholesterol absorption in the intestine. It is being studied in combination with rosuvastatin, a statin, to lower cholesterol levels in patients with hypercholesterolemia.